Candel Therapeutics, Inc. (NASDAQ:CADL) Stock Has Average Price Target of $20.14

Posted by Brian Himes on Oct 9th, 2026

Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) has earned an average rating of “Moderate Buy” from the eleven research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $20.14.

A number of research firms recently commented on CADL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of Candel Therapeutics in a research note on Friday, October 2nd. Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Stifel Nicolaus assumed coverage on Candel Therapeutics in a research report on Monday, July 13th. They set a “buy” rating and a $22.00 target price for the company. Finally, Bank of America raised shares of Candel Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $12.00 to $18.00 in a report on Monday, September 21st.

View Our Latest Stock Analysis on Candel Therapeutics

Candel Therapeutics Stock Performance

CADL opened at $9.66 on Friday. The stock has a market capitalization of $739.18 million, a price-to-earnings ratio of -6.85 and a beta of -0.32. The company has a fifty day moving average of $11.52 and a 200 day moving average of $9.16. Candel Therapeutics has a fifty-two week low of $4.35 and a fifty-two week high of $14.00. The company has a debt-to-equity ratio of 0.38, a quick ratio of 16.09 and a current ratio of 16.09.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.28). As a group, sell-side analysts forecast that Candel Therapeutics will post -1.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of Candel Therapeutics stock in a transaction on Monday, August 17th. The shares were sold at an average price of $12.00, for a total value of $84,000.00. Following the completion of the transaction, the chief technology officer directly owned 76,865 shares of the company’s stock, valued at $922,380. This trade represents a 8.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 14.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CADL. Janus Henderson Group PLC purchased a new position in Candel Therapeutics during the 1st quarter valued at $845,000. BlackRock Inc. purchased a new stake in Candel Therapeutics in the second quarter worth $51,181,000. Wellington Management Group LLP bought a new stake in shares of Candel Therapeutics during the second quarter worth $2,119,000. Bank of New York Mellon Corp bought a new stake in shares of Candel Therapeutics during the second quarter worth $1,975,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Candel Therapeutics during the second quarter valued at $775,000. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

(Get Free Report)

Candel Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing biological immunotherapies designed to stimulate and strengthen the body’s immune response against cancer. The company’s approach uses engineered viruses intended to selectively target tumors and activate broader antitumor immunity.

Candel’s pipeline includes CAN-3110, an investigational oncolytic immunotherapy being developed for high-grade glioma, including recurrent glioblastoma. The company is also developing CAN-2409, a non-replicating adenovirus-based therapy designed to work with a prodrug to trigger localized cancer-cell destruction and immune activation.